Citadel Advisors’s Tenax Therapeutics TENX Stock Holding History

Citadel Advisors’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$531K	Buy	+36,500	New	+$466K	﹤0.01%	9714

Other funds holding TENX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Citadel Advisors's TENX Position: Q2 2026 in Review

Citadel Advisors increased its Tenax Therapeutics (TENX) stake by 378% in Q2 2026, buying an estimated $7.36M and bringing the position to 728,561 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3475.

Citadel Advisors first reported a position in TENX in Q1 2017 and has held it in 20 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

Citadel Advisors held 728,561 shares of Tenax Therapeutics worth $10.6M as of Q2 2026.
Citadel Advisors bought 576,045 Tenax Therapeutics shares in Q2 2026, an estimated $7.36M.
Tenax Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3475 holding.
Citadel Advisors first reported a position in Tenax Therapeutics in Q1 2017 and has held it in 20 quarters since.
111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.